Studien - Niere
   
 

     
AUO Nr.: AN 39/16  Niere   Details zur Studie         
Titel: Keynote-426 - A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC)
Studienleiter: Herr Prof. Dr. med. Jens Bedke - Universitätsklinik Tübingen  72076 Tübingen Hoppe-Seyler-Str. 3 Tel:07071/29-86 613  jens.bedke@med.uni-tuebingen.de

     
AUO Nr.: AN 40/16  Niere   Details zur Studie         
Titel: Keynote-427 - A Phase II Single-arm, Open-label Monotherapy Clinical Trial of Pembrolizumab (MK-3475) in Locally Advanced/Metastatic Renal Cell Carcinoma (mRCC)
Studienleiter: Herr Prof. Dr. med. Jens Bedke - Universitätsklinik Tübingen  72076 Tübingen Hoppe-Seyler-Str. 3 Tel:07071/29-86 613  jens.bedke@med.uni-tuebingen.de

    ../images/log2.gif  
AUO Nr.: AN 43/17 Niere   Details zur Studie         
Titel: A NATIONAL, PROSPECTIVE, NON-INTERVENTIONAL STUDY (NIS) OF NIVOLUMAB (BMS-936558) IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA AFTER PRIOR THERAPY
Studienleiter: Herr Dr. Martin Herber - Bristol-Myers-Squibb GmbH & Co. KGaA  80636 München Arnulfstr. 29 Tel:089/12 142-217  

    ../images/log2.gif  
AUO Nr.: AN 44/17 Niere   Details zur Studie         
Titel: A Phase 3 Randomized Study Compa-ring Nivolumab and Ipilimumab Combi-nation vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrec-tomy and Who Are at High Risk of Relapse
Studienleiter: kein Einverständnis zur Veröffentlichung der Daten. Bitte haben Sie Verständnis dafür!